A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis in vivo

Despite unprecedented efforts, our therapeutic arsenal against SARS-CoV-2 remains limited. The conserved macrodomain 1 (Mac1) in NSP3 is an enzyme exhibiting ADP-ribosylhydrolase activity and a possible drug target. To determine the therapeutic potential of Mac1 inhibition, we generated recombinant...

Descripción completa

Detalles Bibliográficos
Autores principales: Taha, Taha Y., Suryawanshi, Rahul K., Chen, Irene P., Correy, Galen J., O’Leary, Patrick C., Jogalekar, Manasi P., McCavitt-Malvido, Maria, Diolaiti, Morgan E., Kimmerly, Gabriella R., Tsou, Chia-Lin, Martinez-Sobrido, Luis, Krogan, Nevan J., Ashworth, Alan, Fraser, James S., Ott, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153184/
https://www.ncbi.nlm.nih.gov/pubmed/37131711
http://dx.doi.org/10.1101/2023.04.18.537104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153184/
https://www.ncbi.nlm.nih.gov/pubmed/37131711
http://dx.doi.org/10.1101/2023.04.18.537104

Ejemplares similares